WHO’s Ayurveda push applauded but Indian industry calls for clearer regulations to propel growth India’s Ayurveda nutraceuticals and medicines industry players have welcomed efforts by ministers and the World Health Organization (WHO) to promote the safe and effective use of traditional medicines, but has also urged for clearer regulatory guidelines.
India’s Ministry of AYUSH recently signed a letter of exchange with the WHO South East Asia Regional (SEAR) Office in New Delhi on Monday (Feb 15), pledging to integrate these traditional practices into national health care systems.
“As a major outcome of this partnership, the Ministry of AYUSH and WHO would be working to identify various challenges faced by the member states of SEAR in regulating, integrating and further promoting traditional systems of medicine in the respective countries,” the Ministry of AYUSH said.
Ayurveda cannabis firm to focus on chronic pain relief solutions after launching product for menstrual cramps The Indian firm behind an ayurvedic cannabis product for alleviating menstrual cramps has unveiled plans on expanding its product range to cover chronic pain relief.
This could cover pain relief for chronic issues such as arthritis and joint pain, founder Abhishek Mohan told
NutraIngredients-Asia.
“
We will go after mass ailments such as arthritis, joint pain, largely around pain relief.
“The world is also warming up to ayurveda and we are looking to export the products into Canada and Germany,” he said.
According to the company, cannabinoids address chronic pain and produce analgesia by acting on multiple pain targets within the peripheral and central nervous system.